HOOK HOOKIPA Pharma Inc.

12.2
+1.01  (+9%)
Previous Close 11.19
Open 12.4
Price To Book 2.46
Market Cap 309,983,554
Shares 25,408,488
Volume 320,214
Short Ratio
Av. Daily Volume 110,279
Stock charts supplied by TradingView

NewsSee all news

  1. HOOKIPA's Gilead Sciences Collaboration for HIV and HBV Therapeutic Vaccines Advancing Towards Clinical Entry

    NEW YORK and VIENNA, Austria, Jan. 06, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on

  2. HOOKIPA Announces First Patient Dosed in Phase 1/2 Clinical Trial for HB-201 for the Treatment of Human Papillomavirus 16-Positive Cancers

    NEW YORK and VIENNA, Austria, Dec. 30, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on

  3. HOOKIPA Pharma to Present at Piper Jaffray 31st Annual Healthcare Conference

    NEW YORK and VIENNA, Austria, Nov. 25, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on

  4. HOOKIPA Pharma Reports Third Quarter 2019 Financial Results and Provides a Corporate Update

    NEW YORK and VIENNA, Austria, Nov. 12, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on

  5. HOOKIPA Pharma To Report Third Quarter 2019 Financial Results on November 12, 2019

    NEW YORK and VIENNA, Austria, Nov. 04, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 safety data due 1H 2020, with efficacy data due 4Q 2020.
HB-101
Cytomegalovirus (CMV)
Phase 1/2 trial initiation announced December 30, 2019 with with preliminary safety and efficacy data expected in late 2020 or early 2021.
HB-201
Treatment-refractory HPV16+ cancers
IND 1H 2020 with data due mid-2021.
HB-202
HPV16+ Cancer

Latest News

  1. HOOKIPA's Gilead Sciences Collaboration for HIV and HBV Therapeutic Vaccines Advancing Towards Clinical Entry

    NEW YORK and VIENNA, Austria, Jan. 06, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on

  2. HOOKIPA Announces First Patient Dosed in Phase 1/2 Clinical Trial for HB-201 for the Treatment of Human Papillomavirus 16-Positive Cancers

    NEW YORK and VIENNA, Austria, Dec. 30, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on

  3. HOOKIPA Pharma to Present at Piper Jaffray 31st Annual Healthcare Conference

    NEW YORK and VIENNA, Austria, Nov. 25, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on

  4. HOOKIPA Pharma Reports Third Quarter 2019 Financial Results and Provides a Corporate Update

    NEW YORK and VIENNA, Austria, Nov. 12, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on

  5. HOOKIPA Pharma To Report Third Quarter 2019 Financial Results on November 12, 2019

    NEW YORK and VIENNA, Austria, Nov. 04, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on

  6. HOOKIPA Pharma to Present at Upcoming Conferences in November

    NEW YORK and VIENNA, Austria, Oct. 31, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on

  7. HOOKIPA Announces Key Hires to its Executive Team

    Christine D. Baker has joined as Chief Business Officer Roman Necina, PhD, will join as Chief Technology Officer  NEW YORK and VIENNA, Austria, Sept. 25, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK,

  8. HOOKIPA to Present Data Demonstrating the Potential of its TheraT® Technology at the Upcoming CICON Conference in Paris

    NEW YORK and VIENNA, Austria, Sept. 19, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on